Budgetary impact of emicizumab versus activated prothrombin complex concentrate (aPCC) for the prophylactic treatment of hemophilia A with inhibitors
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.163.1977Keywords:
emicizumab, Hemlibra, aPCC, AICC, Factor VIIa, budgetary impact, hemophilia A, inhibitorAbstract
Objective: to analyze the budgetary impact of emicizumab compared to activated prothrombin complex concentrate (aPCC) for the prophylactic treatment of hemophilia A with inhibitors. Material and methods: A budget impact analysis in a hypothetical cohort of 26 Peruvian patients with Hemophilia A with inhibitors. The data comes from scientific articles published in peer-reviewed journals. Three scenarios were considered: the e calculated without bleeding episode costs, the price calculated with bleeding episodes treated with aPCC, and the price calculated with bleeding episodes treated with rFVIIa. Results: The savings for using emicizumab range from S/. 67,531,645 to S/. 120,176,763.84, the most likely being S/. 111,008,056.32. In the most conservative scenario, which assumes that the prophylactic use of emicizumab and aPCC have the same risk of annual bleeding episodes, prophylaxis for two years with emicizumab would mean savings of S/.111,008,056.32 or S/ 67,531,645.4 when compared with the prophylactic use of aPCC at doses of 100 IU/Kg or 70 IU/kg every other day, respectively. The scenario that presents the greatest savings is the one assuming that emicizumab reduces the risk of annual bleeding episodes more than aPCC, and both use rFVIIa for the treatment of bleeding episodes. In this scenario, savings could be S/.120,176,763.84 or S /.76,700,352.96 when compared with the prophylactic use of aPCC at doses of 100 IU/Kg or 70 IU/kg every other day, respectively. Conclusions: Emicizumab has a lower financial impact than aPCC.
Downloads
Metrics
References
Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, et al. Haemophilia. Nat Rev Dis Primer. diciembre de 2021;7(1):45. doi: 10.1038/s41572-021-00278-x.
Kizilocak H, Young G. Diagnosis and treatment of hemophilia. Clin Adv Hematol Oncol HO. junio de 2019;17(6):344–51. Disponible en: https://www.hematologyandoncology.net/archives/june-2019/diagnosis-and-treatment-of-hemophilia/
FEDERACIÓN MUNDIAL DE HEMOFILIA. INFORME DEL SONDEO MUNDIAL ANUAL 2021 [Internet]. 2022. Disponible en: https://www1.wfh.org/publications/files/pdf-2324.pdf. .
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020: 26(Suppl 6): 1-158. https://doi.org/10.1111/hae.14046. .
FEDERACIÓN MUNDIAL DE HEMOFILIA. INFORME DEL SONDEO MUNDIAL ANUAL 2020 [Internet]. 2021 oct. Disponible en: https://www1.wfh.org/publications/files/pdf-2045.pdf. .
Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors. N Engl J Med. el 3 de noviembre de 2011;365(18):1684–92. Doi: 10.1056/NEJMoa1104435.
Montaño CA, Cruz MS, Lemos F, Quiroz A, Rojas G. Diagnostic and therapeutic status of haemophilia in Latin America. J Haemoph Pract. el 1 de mayo de 2013;1(2):30–4. Doi: https://doi.org/10.17225/jhp.00022.
IETSI. GUÍA DE PRÁCTICA CLÍNICA PARA EL DIAGNÓSTICO Y TRATAMIENTO DE HEMOFILIA. 2021;24. Disponible en: https://gpc-peru.com/gpchemofilia
American Society of Hematology. The High Price of Hemophilia. el 30 de diciembre de 2021 [citado el 9 de febrero de 2023]; Disponible en: https://ashpublications.org/ashclinicalnews/news/4932/The-High-Price-of-Hemophilia?searchresult=1. .
Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. enero de 2014;17(1):5–14. doi: 10.1016/j.jval.2013.08.2291.
Bitrán R, Peña C, Arpón P, Loayza N, Salas K, del Villar C, et al. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru. Medwave. el 31 de marzo de 2022;22(02):e002118–e002118. doi: 10.5867/medwave.2022.02.002118
Loayza N. EXPERIENCIA EN EL MANEJO DE HEMOFILIA EN EL HOSPITAL NACIONAL DOS DE MAYO: 2000-2015. LIMA-PERU. Revista Médica Carrionica [Internet]. 2016;3(3). Disponible en:. https://www.semanticscholar.org/paper/EXPERIENCIA-EN-EL-MANEJO-DE-HEMOFILIA-EN-EL-DOS-DE-Urcia/ac927bcd4439a4abe4724aa9213299fd49310c09. .
Álvarez M. (2022). Guías españolas para el manejo del paciente con hemofilia. Madrid, España: Aran ediciones s.l. Disponible en: https://rfve.es/wp-content/uploads/GUIAS-espanolas-hemofilia-RFVE-26_06.pdf.
Brackmann HH, Schramm W, Oldenburg J, Cano V, Turecek PL, Négrier C. Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors. Hamostaseologie. diciembre de 2020;40(5):606–20. doi: 10.1055/a-1159-4273
Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman‐Becerra N, et al. Randomized comparison of prophylaxis and on‐demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. enero de 2014;20(1):65–72. doi: 10.1111/hae.12246.
Agencia española de medicamentos y productos sanitarios. Ficha técnica FEIBA 25 U/ml polvo y disolvente para solución para perfusión [Internet]. 2020. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/80118/FT_80118.pdf.
Hedner U. Mechanism of Action of Recombinant Activated Factor VII: An Update. Semin Hematol. enero de 2006;43:S105–7. doi: 10.1053/j.seminhematol.2005.11.025.
(FDA. NovoSeven RT (rFVIIa). FDA [Internet]. el 24 de febrero de 2023 [citado el 24 de febrero de 2023]; Disponible en: https://www.fda.gov/media/70442/download).
Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, Cetkovsky P, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia. mayo de 2009;15(3). doi: 10.1111/j.1365-2516.2009.02007.x.
Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. Eur J Haematol. febrero de 2019;102(2):111–22. doi: 10.1111/ejh.13193.
Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. el 22 de abril de 2021;137(16):2231–42. doi: 10.1182/blood.2020009217 .
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. el 31 de agosto de 2017;377(9):809–18. DOI: 10.1056/NEJMoa1703068.
Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman‐Becerra N, et al. Randomized comparison of prophylaxis and on‐demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. enero de 2014;20(1):65–72. Doi: 10.1111/hae.12246.
FDA. NovoSeven® RT, Coagulation Factor VIIa (Recombinant) [Internet]. 2014. Disponible en: https://www.fda.gov/media/70442/download. .
IETSI. Dictamen preliminar de evaluación de tecnología sanitaria N° 047-DETS-IETSI-2022, Eficacia y seguridad de emicizumab en pacientes pediátricos con diagnóstico de hemofilia A (deficiencia congénita del factor VIII). con presencia de anticuerpos inhibidores del factor VIII y que fracasan o no son candidatos a la terapia de inmunotolerancia con factor VIII [Internet]. 2022. Disponible en: https://ietsi.essalud.gob.pe/wp-content/uploads/2022/12/Dict.-047-DETS-2022.pdf.
Blanco J, Bustamante A, Muñoz A. Análisis de impacto presupuestal sobre el uso de emicizumab en profilaxis para Hemofilia A severa e inhibidores en población pediátrica de República Dominicana. 2021;18. .
IETSI, Guía de práctica clínica para el diagnóstico y tratamiento de hemofilia en el Seguro Social de Salud del Perú (EsSalud). An Fac med. 2018;79(1):83-93 DOI: http:// dx.doi.org/10.15381/anales.v79i1.14598.
Linari S, Castaman G. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence. Ther Clin Risk Manag. 2020 May 22;16:461-469. doi: 10.2147/TCRM.S205310. PMID: 32547043; PMCID. : PMC7251291. .
Samelson‐Jones BJ, Guelcher C, Kuhn J, Butler R, Massey G, Guerrera MF, et al. Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. julio de 2021;27(4):591–8. doi: 10.1111/hae.14347.
Instituto de Evaluación y Gestión de Tecnologías Santiarias. Emicizumab en comparación con CCPA en el tratamiento de pacientes con hemofilia A congénita severa e inhibidores contra el FVIII. Febrero de 2022. https://www.igets.com.pe/_files/ugd/7ac458_5f0421b90f8b4f3a94841c9b371910c8.pdf
Downloads
Published
How to Cite
License
Copyright (c) 2023 Victor Dongo
This work is licensed under a Creative Commons Attribution 4.0 International License.
